argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The CEO, Tim Van Hauwermeiren, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [1] - A live webcast of the presentation will be available on the argenx website, with a replay accessible for approximately 30 days [2] Company Overview - argenx partners with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into novel antibody-based medicines [3] - The company has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker globally, with approvals in the U.S., Japan, Israel, the EU, the UK, China, and Canada [3] - argenx is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier-stage experimental medicines within its therapeutic franchises [3]